|
09 Aug 2025 |
Divi's Laboratories
|
Consensus Share Price Target
|
5914.50 |
6383.55 |
- |
7.93 |
hold
|
|
|
|
|
05 Feb 2023
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
5914.50
|
2700.00
|
2884.35
(105.05%)
|
|
Hold
|
|
|
|
|
04 Feb 2023
|
Divi's Laboratories
|
BOB Capital Markets Ltd.
|
5914.50
|
3200.00
|
2884.35
(105.05%)
|
Target met |
Hold
|
|
|
Q3 disappoints as revenue/PAT of Rs 17bn/Rs 3bn missed consensus by 12%/38%
|
|
04 Feb 2023
|
Divi's Laboratories
|
Motilal Oswal
|
5914.50
|
2620.00
|
2884.35
(105.05%)
|
|
Neutral
|
|
|
|
|
03 Feb 2023
|
Divi's Laboratories
|
ICICI Direct
|
5914.50
|
2945.00
|
2884.35
(105.05%)
|
Target met |
Hold
|
|
|
|
|
11 Nov 2022
|
Divi's Laboratories
|
SMC online
|
5914.50
|
|
3271.40
(80.79%)
|
|
Results Update
|
|
|
|
|
09 Nov 2022
|
Divi's Laboratories
|
BOB Capital Markets Ltd.
|
5914.50
|
3450.00
|
3298.75
(79.30%)
|
Target met |
Hold
|
|
|
Q2 revenue fell 7% YoY to Rs 18.5bn, weighed down by a decline in custom synthesis business
|
|
08 Nov 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
5914.50
|
3893.00
|
3414.55
(73.21%)
|
Target met |
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) Q2FY23 performance was sharply below our estimates. Consolidated revenue fell 6.7% YoY to Rs18.5bn (I-Sec: Rs22.9bn), EBITDA margin slipped 770bps YoY to 33.5% (I-Sec: 41.2%) and adjusted PAT declined 18.6% YoY to Rs4.9bn (I-Sec: Rs6.2bn).
|
|
08 Nov 2022
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
5914.50
|
3300.00
|
3298.75
(79.30%)
|
Target met |
Hold
|
|
|
|
|
08 Nov 2022
|
Divi's Laboratories
|
ICICI Direct
|
5914.50
|
3685.00
|
3414.55
(73.21%)
|
Target met |
Hold
|
|
|
|
|
03 Oct 2022
|
Divi's Laboratories
|
Ashika Research
|
5914.50
|
4110.00
|
3726.85
(58.70%)
|
|
Buy
|
|
|
|